Cordblood(commonlyabbreviatedHUCB)CD34+cellsareknowntocontainhematopoieticstemandProgenitorcells,andareidealforstudiesrelatingtotransplantationandstemcellsascordbloodderivedcellstendtobemorenaïvethansimilarcellsderivedfromothertissuesources.

HighPurityandViABIlity 

LonzacordbloodCD34+cellsareisolatedfromcordbloodmononuclearcells(MNCs)viapositiveimmunomagneticseparationandareguaranteedtohaveapurityof≥90%asindicatedbyCD34+expressingcells.Theyare guaranteedtocontaineither≥100,000,≥500,000,or≥1millionviablecellsperampouledependingontheproductordered.HIV-1andhepatitisBarenotdetectedforalldonorsand/orcelllots.ACertificateofAnalysisisprovidedforeachcelllotpurchased.

Budgetcellsguaranteedtohaveapurityof80-89%asindicatedbyCD34+expressingcellsarealsoavailableatadiscountedratein≥500,000(2C-101AS)or≥1million(2C-101S)viablecellssizes.Contact CustomerServicefororderinginformation.

ChoicesinTissueSource

CordbloodCD34+cellstendtobemorenaivethanhematopoieticstemcellsfromothertissuesources.Thus,theycanbeagreattoolwhentryingtobypassHLAmismatchissues.However,thenumberofcellsavailableperdonorislimitedandcanposeachallengeinyourresearch.Ifyouarelookingforlargenumbersofhematopoieticstemcellsfromthesamedonor,CD34+cellsderivedfrombonemarrowmightbeagoodoption.

SupportedbyanOptimizedMediaSystem

HPGM™HematopoieticGrowthMedium isrecommendedforoptimalperformanceinserum-freeculturing(additionalcytokinesmaybenecessarydependingonapplication).Alternativemediacontainingserummayalsobeacceptable.PleasecontactScientificSupportforserumcontainingmediarecommendations.

LonzaguaranteestheperformanceofClonetics™/Poietics™cellsonlyifappropriateClonetics™/Poietics™mediaandreagentsareusedexclusivelyandtherecommendedstorageanduseprotocolsarefollowed.Anymodificationsmadetotherecommendedcellsystemsincludingtheuseofalternativemedia,reagentsorprotocols,willvoidcellandmediaperformanceguarantees.Ifyouneedassistanceinselectingtheappropriatemedia,reagents,orprotocol,pleasecontactLonzaScientificSupport.

龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach，公司经营范围包括：生物技术开发服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术推广服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术咨询、交流服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术转让服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;医学研究和试验发展（人体干细胞、基因诊断与治疗技术除外）;药品研发（人体干细胞、基因诊断与治疗技术除外）;货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易（涉及外资准入特别管理规定和许可审批的商品除外）;生物药品制造;化学药品原料药制造;化学药品制剂制造等。